Loading...
•
Dec 31, 2021
Royalty Pharma Q4 2021 Earnings Report
Reported financial results for Q4 and full year 2021, and introduced 2022 Adjusted Cash Receipts guidance.
Key Takeaways
Royalty Pharma reported strong Q4 and full year 2021 results, with Adjusted Cash Receipts growing by 12% in Q4 and 18% for the full year. The company also announced transactions of $3.0 billion in 2021 and introduced 2022 Adjusted Cash Receipts guidance of $2,225 to $2,300 million.
Net cash provided by operating activities (GAAP) was $490 million.
Adjusted Cash Receipts (non-GAAP) reached $543 million.
Adjusted Cash Flow (non-GAAP) was $488 million.
Announced transactions of up to $3.0 billion in 2021, including $2.3 billion in upfront payments.
Royalty Pharma
Royalty Pharma
Royalty Pharma Revenue by Segment
Revenue by Segment
Cystic Fibrosis Franchise Revenue
CapyFin.comTysabri Revenue
CapyFin.comEvrysdi Revenue
CapyFin.comXtandi Revenue
CapyFin.comImbruvica Revenue
CapyFin.comPromacta Revenue
CapyFin.comTremfya Revenue
CapyFin.comCabometyx/Cometriq Revenue
CapyFin.comTrodelvy Revenue
CapyFin.comErleada Revenue
CapyFin.comOther Products Revenue
CapyFin.com Forward Guidance
Royalty Pharma expects 2022 Adjusted Cash Receipts to be between $2,225 million and $2,300 million, excluding new transactions announced after the date of this release.